Abstract: The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist.
Type:
Grant
Filed:
February 1, 2016
Date of Patent:
November 27, 2018
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Amjad Ali, Rongze Kuang, Yeon-Hee Lim, Michael Man-Chu Lo, Pauline C. Ting, Purakkattle Biju, Manuel de Lera Ruiz, Sylvia J. Degrado, Alexander L. Tung, Timothy J. Henderson, Liwu Hong, Jae-Hun Kim, Dong Won-Shik Kim, Joe Lee, Jie Wu, Heping Wu, Yushi Xiao, Tao Yu, Gang Zhou, Xiaohong Zhu, Kevin D. McCormick, Jayaram R. Tagat, Dong Xiao, Tanweer Khan, Jianhua Cao, Michael Berlin, Yonglian Zhang
Abstract: The invention relates to a method for the production and non-covalent surface display of antibodies and derived fragments as well as molecule libraries based thereon on the surface of S. cerevisiae cells. The non-covalent manner of the surface display renders possible the selection of specific variants by means of high throughput screening and the subsequent switchable secretion of the selected binding molecule into the culture supernatant for biochemical characterization.
Type:
Grant
Filed:
December 11, 2013
Date of Patent:
November 27, 2018
Assignee:
MERCK PATENT GmbH
Inventors:
Ralph Guenther, Bjoern Hock, Stefan Becker, Laura Rhiel
Abstract: A sample preparation device, preferably for sterility testing, comprising a manifold including one or more receptacles for filtration units and at least one inlet and/or outlet port. The receptacle(s) is/are respectively provided with one or more connectors for establishing a fluid connection with mating ports of the filtration units and media containers/vials upon insertion of the same into the respective receptacles. The connectors are in fluid communication with the inlet and outlet port(s) via channels defined in the manifold to allow a desired fluid transfer through the manifold.
Type:
Grant
Filed:
June 14, 2013
Date of Patent:
November 27, 2018
Assignee:
MERCK PATENT GMBH
Inventors:
Stephane Olivier, Pierre Guedon, Florian Allard
Abstract: The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.
Inventors:
Peter D. Williams, John A. McCauley, Christopher J. Bungard, David Jonathan Bennett, Sherman T. Waddell, Gregori J. Morriello, Lehua Chang, Michael P. Dwyer, M. Katharine Holloway, Alejandro Crespo, Xin-Jie Chu, Catherine Wiscount, H. Marie Loughran, Jesse J. Manikowski, Jurgen Schulz, Kartik M. Keertikar, Bin Hu, Bin Zhong, Tao Ji
Abstract: The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses. In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4. The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. Also provided herein are methods of inducing a protective immune response in a human patient population by administering the compositions described herein to the patients.
Type:
Grant
Filed:
September 22, 2015
Date of Patent:
November 27, 2018
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Beth-Ann Griswold Coller, Vidya B. Pai, Jr., D. Elliot Parks, Michele Yelmene, Andrew J. Bett, Timothy Martyak
Abstract: The present invention relates to a compound of the formula (I), to the use of this compound in an electronic device, and to an electronic device comprising one or more compounds of the formula (I). The invention furthermore relates to the preparation of the compound of the formula (I) and to a formulation comprising one or more compounds of the formula (I).
Type:
Grant
Filed:
March 2, 2017
Date of Patent:
November 27, 2018
Assignee:
Merck Patent GmbH
Inventors:
Philipp Stoessel, Arne Buesing, Frank Voges, Christof Pflumm, Amir Parham, Thomas Eberle, Teresa Mujica-Fernaud
Abstract: The present invention relates to liquid crystal media comprising polymerizable mesogenic compounds with a bent shape, and to electro-optical displays comprising these media as light modulation media. In particular the electro-optical displays according to the present invention are displays, which are operated at a temperature, at which the liquid crystal modulation media are in an optically isotropic phase, preferably in a blue phase.
Type:
Grant
Filed:
July 17, 2015
Date of Patent:
November 27, 2018
Assignee:
Merck Patent GmbH
Inventors:
Michael Wittek, Norihiko Tanaka, Kevin Adlem, Matthias Bremer, David Wilkes, Ming-Chou Wu
Abstract: The present invention relates to imidazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
Type:
Grant
Filed:
June 24, 2014
Date of Patent:
November 27, 2018
Assignee:
Merck Patent GmbH
Inventors:
Henry Yu, Thomas E. Richardson, Marianne Donnelly, Ngan Nguyen, Xuliang Jiang
Abstract: A layer arrangement (1) which changes the transmission of incident light depending on its temperature, where the layer arrangement (1) has a first polarization layer (5a), a switching layer (2) which influences the polarization properties of light depending on the temperature, and a second polarization layer (5b), whereby both the first polarization layer (5a) and the second polarization layer (5b) are arranged to affect polarization both in the VIS region and in the NIR region.
Abstract: Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-PD-1 antibodies or antigen-binding fragments thereof (e.g., pembrolizumab) are provided. Methods of administering the combinations to treat cancers, e.g., ovarian, peritoneal, or fallopian tube cancers, with greater clinical efficacy and/or decreased toxicity are also provided.
Abstract: The present application relates to novel compounds and to devices which contain these compounds. The application also relates to a device for regulating the passage of energy from an outside space into an inside space, to a window containing the said device, and to uses of the said devices and compounds.
Type:
Application
Filed:
November 11, 2015
Publication date:
November 22, 2018
Applicant:
Merck Patent GmbH
Inventors:
Peer KIRSCH, Susann BECK, Michael JUNGE, Andreas BEYER, Ursula PATWAL
Abstract: The present invention relates, inter alia, to dermal systems comprising at least one light source and at least one pharmaceutically and/or cosmetically active ingredient. The dermal systems can be employed in order to enhance the penetration and action of the pharmaceutically and/or cosmetically active ingredient.
Type:
Grant
Filed:
January 11, 2017
Date of Patent:
November 20, 2018
Assignee:
Merck Patent GmBh
Inventors:
Herwig Buchholz, Ewald Aydt, Junyou Pan
Abstract: The invention relates to the compounds of the formula I and to a liquid-crystalline medium based on a mixture of polar compounds which contains at least one compound of the formula I in which R1, ring A1, L1, L2, L3, L4, L5, L6, L7, L8, Z1 and m have the meanings indicated in claim 1 and to the use of the LC mixtures in electro-optical displays, especially for the self-aligning VA mode.
Type:
Grant
Filed:
December 15, 2014
Date of Patent:
November 20, 2018
Assignee:
Merck Patent GmbH
Inventors:
Graziano Archetti, Izumi Saito, Rocco Fortte, Timo Uebel
Abstract: Intelligent cold storage system for storing pharmaceutical product containers, such as vials, ampules, syringes, bottles, medication tubes, blister packs and cartons, at the point of dispensing. Embodiments of the invention use product identification technology, such as radio-frequency identification (RFID) tags and barcode readers, to uniquely identify containers as they are added to or removed from the cold storage compartment, and automatically retrieve from a local or remote database a variety of details associated with the containers and their contents, such as manufacturing data, expiration dates, time out of refrigeration, inventory levels, safety information, usage statistics, known contraindications and warnings, etc. If the details indicate that there is a problem with a particular pharmaceutical (e.g.
Abstract: The present invention relates to an electronic device comprising anode, cathode and at least one organic layer which comprises a compound of the formula (I) to (IV). The invention furthermore encompasses the use of compounds of the formula (I) to (IV) in an electronic device and to a compound of the formula (Ic) to (IVc).
Type:
Grant
Filed:
June 26, 2017
Date of Patent:
November 20, 2018
Assignee:
Merck Patent GmbH
Inventors:
Philipp Stoessel, Arne Buesing, Dominik Joosten
Abstract: The present invention relates to a novel process for the preparation of printable, high-viscosity oxide media, and to the use thereof in the production of solar cells.
Type:
Grant
Filed:
December 18, 2013
Date of Patent:
November 20, 2018
Assignee:
MERCK PATENT GMBH
Inventors:
Ingo Koehler, Oliver Doll, Sebastian Barth
Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
Type:
Grant
Filed:
December 17, 2015
Date of Patent:
November 20, 2018
Assignee:
MERCK SHARP & DOHME CORP.
Inventors:
Jian Liu, Joseph A. Kozlowski, Abdul-Basit Alhassan, Rajan Anand, Sobhana Babu Boga, Deodial Guy Guiadeen, Wensheng Yu, Younong Yu, Shilan Liu, Hao Wu, Chundao Yang
Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
Type:
Grant
Filed:
August 5, 2015
Date of Patent:
November 20, 2018
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Harry Chobanian, Duane DeMong, Christopher W. Plummer, Minghai Fang, Bin Hu
Abstract: The present invention is directed to a process for preparing Substituted Indole Compounds of Formula (I): wherein R1, R2, R3 and R4 are as defined herein. These indole compounds are useful as synthetic intermediates for making inhibitors of HCV NS5A.
Type:
Grant
Filed:
November 5, 2015
Date of Patent:
November 20, 2018
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Daniel A. DiRocco, Ian Davies, Feng Peng, Mark McLaughlin, Louis-Charles Campeau, Yingju Xu
Abstract: The present invention relates to a rotary printing process for the application of functional coatings to a print substrate, to a coated print substrate produced by the said process, and to the use thereof, in particular in the packaging sector.
Type:
Grant
Filed:
October 28, 2014
Date of Patent:
November 20, 2018
Assignee:
MERCK PATENT GMBH
Inventors:
Andreas Becker, Thomas Rathschlag, Johannes Tasch